Spanish multicenter tafluprost tolerability study

Millá, Elena; Stirbu, Oana; Rey, Amanda; Duch, Susana; Buchacra, Oscar; Robles, Amelia y Belén; Navarro, Catalina; Gil, Rafael Barquín; Cordero, José María

doi:10.1136/bjophthalmol-2011-301015

Cited by 17 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, these investigations have reported a mean diurnal IOP reduction of 22.9–32.1% from untreated baseline 13 16 28. Although these studies do not provide controlled observations, they indicate that PF tafluprost has almost comparable efficacy to latanoprost and will likely benefit patients facing tolerability problems with other medications.…”

Section: Discussionmentioning

confidence: 96%

“…Several open label non-interventional studies have examined the efficacy and tolerability of PF tafluprost in naïve16 or previously treated patients with open angle glaucoma or OHT, who were either poorly controlled or had tolerability issues with other medications 12–15 28. Overall, these investigations have reported a mean diurnal IOP reduction of 22.9–32.1% from untreated baseline 13 16 28.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

et al. 2013

View full text Add to dashboard Cite

AimTo compare 24 h intraocular pressure (IOP) control obtained with preservative free (PF) tafluprost 0.0015% versus branded preservative containing latanoprost 0.005% administered as first choice monotherapy in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT). Methods This prospective, observer-masked, crossover study included consecutive newly diagnosed patients with POAG or OHT, and baseline IOP between 24 and 33 mm Hg. Qualifying patients underwent baseline untreated 24 h IOP monitoring in habitual positions,

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In the study by Milla et al, for the subgroup of patients who had been first treated with a preserved prostaglandin the incidence of hyperemia decreased from 64 to 12%, 3 months after switching to preservative-free tafluprost [40]. There was also a statistically significant decrease in the amount of punctate corneal erosions as well as blepharitis accompanied by an increase in the height of the tear meniscus.…”

Section: Safety and Tolerabilitymentioning

confidence: 86%

“…Finally, its availability as a preservative-free formulation has demonstrated numerous advantages to corneal epithelial cell viability in vitro and in vivo. Lack of preservatives has also translated clinically, leading to a fivefold decrease in injection in one study [40].…”

Section: Expert Commentarymentioning

confidence: 98%

See 1 more Smart Citation

Tafluprost in the treatment of glaucoma

Kaplowitz¹,

Tsai

2012

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages

Holló

Katsanos

Boboridis

et al. 2017

Drugs

View full text Add to dashboard Cite

Glaucoma therapy-related ocular surface disease (OSD) is a serious pathology with a broad spectrum of insidious clinical presentations and complex pathogenesis that undermines long-term glaucoma care. Preservatives, especially benzalkonium chloride (BAK), contained in topical intraocular pressure-lowering medications frequently cause or aggravate OSD in glaucoma. Management of these patients is challenging, and to date often empirical due to the scarcity of controlled long-term clinical trials. Most of the available data are extracted from case series and retrospective analysis. Preservative-free prostaglandins and prostaglandin/timolol fixed combinations are novel options developed to remove the harmful impact of preservatives, especially BAK, upon ocular tissues. Based on what is currently known on the value of preservative-free antiglaucoma therapies it is tempting to speculate how these new therapies may affect the future medical management of all glaucoma patients. This article provides a comprehensive and critical review of the current literature on preservative-free prostaglandins and preservative-free prostaglandin/timolol fixed combinations.

show abstract

Spanish multicenter tafluprost tolerability study

Abstract: Preservative-free tafluprost is a well tolerated hypotensive agent that can be used in eyes with surface problems and in naive eyes.

Cited by 17 publications

References 19 publications

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

Tafluprost in the treatment of glaucoma

Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages

Contact Info

Product

Resources

About